

# Miguel Coelho

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4315109/miguel-coelho-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

89  
papers

4,232  
citations

29  
h-index

64  
g-index

97  
ext. papers

5,115  
ext. citations

4.4  
avg, IF

5.03  
L-index

#	Paper	IF	Citations
89	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26 Suppl 3, S42-80	7	599
88	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26 Suppl 3, S2-41	7	397
87	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Movement Disorders</i> , <b>2019</b> , 34, 180-198	7	357
86	International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1248-1266	7	323
85	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , <b>2013</b> , 12, 264-74	24.1	322
84	Convergence of miRNA expression profiling, Synuclein interacton and GWAS in Parkinson's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e25443	3.7	184
83	Red flags for multiple system atrophy. <i>Movement Disorders</i> , <b>2008</b> , 23, 1093-9	7	168
82	Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , <b>2010</b> , 25, 2604-12	7	155
81	Late-stage Parkinson disease. <i>Nature Reviews Neurology</i> , <b>2012</b> , 8, 435-42	15	138
80	Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. <i>Parkinsonism and Related Disorders</i> , <b>2010</b> , 16, 237-42	3.6	108
79	Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. <i>Journal of Neurology</i> , <b>2010</b> , 257, 1524-325	3.5	89
78	DAT imaging in drug-induced and psychogenic parkinsonism. <i>Movement Disorders</i> , <b>2003</b> , 18 Suppl 7, S28-33	3	88
77	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , <b>2006</b> , 21, 809-15	7	83
76	Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Archives of Neurology</i> , <b>2011</b> , 68, 223-30	7	73
75	Therapeutic interventions for symptomatic treatment in Huntington's disease. <i>The Cochrane Library</i> , <b>2009</b> , CD006456	5.2	67
74	High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. <i>Movement Disorders</i> , <b>2007</b> , 22, 1194-201	7	66
73	The European Multiple System Atrophy-Study Group (EMSA-SG). <i>Journal of Neural Transmission</i> , <b>2005</b> , 112, 1677-86	4.3	63

72	Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 540-6	6	62
71	Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 953-9	7	54
70	Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 13713	4.9	46
69	Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 26, 10-6	3.6	44
68	Botulinum toxin type-B improves sialorrhea and quality of life in bulbar onset amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , <b>2008</b> , 255, 545-50	5.5	40
67	Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 737-742	2.2	38
66	Assessment of time perception: the effect of aging. <i>Journal of the International Neuropsychological Society</i> , <b>2004</b> , 10, 332-41	3.1	38
65	Paralytic shellfish poisoning due to ingestion of <i>Gymnodinium catenatum</i> contaminated cockles--application of the AOAC HPLC official method. <i>Toxicon</i> , <b>2012</b> , 59, 558-66	2.8	34
64	Therapeutic interventions for disease progression in Huntington's disease. <i>The Cochrane Library</i> , <b>2009</b> , CD006455	5.2	33
63	Skin cancer and Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 139-48	7	33
62	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 432	4.1	31
61	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 39, 37-43	3.6	29
60	Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 491-501	5.3	29
59	Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson's disease: the Barcelona-Lisbon cohort. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 305-12	6	29
58	Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157852	3.7	29
57	Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. <i>Clinical Neuropharmacology</i> , <b>2008</b> , 31, 2-18	1.4	25
56	Cognitive Impairment in Fall-Related Studies in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 453-69	5.3	22
55	What motivates Parkinson's disease patients to enter clinical trials?. <i>Parkinsonism and Related Disorders</i> , <b>2011</b> , 17, 667-71	3.6	22

54	Prescribing patterns of antiparkinsonian agents in Europe. <i>Movement Disorders</i> , <b>2010</b> , 25, 1053-60	7	18
53	STN-DBS does not change emotion recognition in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 166-9	3.6	17
52	Action verbal fluency in Parkinson's patients. <i>Arquivos De Neuro-Psiquiatria</i> , <b>2015</b> , 73, 520-5	1.6	15
51	Skin cancers and precancerous lesions in Parkinson's disease patients. <i>Movement Disorders</i> , <b>2007</b> , 22, 1471-1475	7	15
50	Fou rire prodromique. Case report and systematic review of literature. <i>Cerebrovascular Diseases</i> , <b>2003</b> , 16, 101-4	3.2	15
49	Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 64, 73-81	3.6	14
48	The management of cervical dystonia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 129-40	4	14
47	The late stage of Parkinson's -results of a large multinational study on motor and non-motor complications. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 75, 91-96	3.6	14
46	Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2017</b> , 41, 113-117	3.6	12
45	Circulating Inflammatory miRNAs Associated with Parkinson's Disease Pathophysiology. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	12
44	Treatment options for non-motor symptoms in late-stage Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 523-35	4	12
43	Subthalamic deep brain stimulation effects on odor identification in Parkinson's disease. <i>European Journal of Neurology</i> , <b>2015</b> , 22, 207-10	6	11
42	Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease. <i>Journal of Parkinson &amp; Disease</i> , <b>2015</b> , 5, 561-7	5.3	11
41	Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , <b>2016</b> , 7, 27	4.1	11
40	Advanced Parkinson disease patients have impairment in prosody processing. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2016</b> , 38, 208-16	2.1	10
39	Time Perception in Mild Cognitive Impairment: Interval Length and Subjective Passage of Time. <i>Journal of the International Neuropsychological Society</i> , <b>2016</b> , 22, 755-64	3.1	9
38	Phenotypic variability of familial and sporadic Progranulin p.Gln257Profs*27 mutation. <i>Journal of Alzheimer &amp; Disease</i> , <b>2013</b> , 37, 335-42	4.3	8
37	Abnormal transcranial magnetic stimulation in a patient with presumed psychogenic paralysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2008</b> , 79, 1412-3	5.5	8

36	Mycoplasma pneumoniae causing nervous system lesion and SIADH in the absence of pneumonia. <i>Clinical Neurology and Neurosurgery</i> , <b>2004</b> , 106, 129-31	2	8
35	Reversible iatrogenic subacute cerebellar syndrome, myoclonus and MRI findings following metronidazole administration. <i>BMJ Case Reports</i> , <b>2009</b> , 2009,	0.9	8
34	The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 531-542	2.2	7
33	Has "levodopa-induced neuropathy" been reported in Parkinson's disease clinical trials?. <i>Movement Disorders</i> , <b>2011</b> , 26, 1966-7	7	7
32	STN-DBS does not change emotion recognition in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 564-5	3.6	6
31	Referral to rehabilitation in Parkinson's disease: who, when and to what end?. <i>Arquivos De Neuro-Psiquiatria</i> , <b>2013</b> , 71, 967-72	1.6	6
30	A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. <i>BMC Neurology</i> , <b>2020</b> , 20, 432	3.1	5
29	Pure ataxia associated with N-methyl-D-aspartate receptor antibodies. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 568-9	3.6	4
28	Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS. <i>Journal of Parkinson &amp; Disease</i> , <b>2017</b> , 7, 255-261	5.3	3
27	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. <i>Journal of Parkinson &amp; Disease</i> , <b>2020</b> , 10, 1171-1184	5.3	3
26	Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 1331-1333	7	3
25	Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 897-900	3.6	3
24	Left hemibody myoclonus due to anomalous right vertebral artery. <i>Movement Disorders</i> , <b>2005</b> , 20, 72-5	7	3
23	Myeloradiculopathy associated to Schistosoma mansoni. <i>BMJ Case Reports</i> , <b>2011</b> , 2011,	0.9	3
22	Levodopa response in later stages of Parkinson's disease: A case-control study. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 77, 160-162	3.6	3
21	miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 661461	5.7	3
20	Vernet syndrome resulting from varicella zoster virus infection-a very rare clinical presentation of a common viral infection. <i>Journal of NeuroVirology</i> , <b>2018</b> , 24, 379-381	3.9	2
19	Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism. <i>Movement Disorders</i> , <b>2013</b> , 28, 1212-4	7	2

18	Sighs during sleep in multiple system atrophy. <i>Sleep Medicine</i> , <b>2021</b> , 78, 75-80	4.6	2
17	Suicidal behaviors are very rare in antiparkinsonian drug trials. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 1008-9	3.6	1
16	I21 Causes Of Death In A European Huntington's Disease Cohort (registry). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, A64-A65	5.5	1
15	Spinal cord astrocytoma mimicking multifocal myelitis. <i>Journal of Spinal Cord Medicine</i> , <b>2014</b> , 37, 429-31	1.9	1
14	Therapeutic interventions for symptomatic treatment in Huntington's disease <b>2007</b> ,		1
13	The Natural History of Parkinson's Disease <b>2017</b> , 129-137		1
12	Musician's Dystonia as the Initial Presentation of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2016</b> , 3, 624-625	2.2	1
11	Epidemiology of Levodopa-Induced Dyskinesia <b>2014</b> , 33-50		1
10	A rare cause of orofacial dyskinesias. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 50, 122-123	3.6	0
9	Facial myokymia and autonomic synkinesis responsive to carbamazepine. <i>Revue Neurologique</i> , <b>2015</b> , 171, 88-9	3	0
8	High frequency of psychosis in late-stage Parkinson's disease.. <i>Clinical Parkinsonism &amp; Related Disorders</i> , <b>2021</b> , 5, 100119	0.9	0
7	Clinical Diagnostic Criteria Have a High Impact on the Frequency of Dementia in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 652424	4.1	0
6	Profile of cognitive impairment in late-stage Parkinson's disease.. <i>Brain and Behavior</i> , <b>2022</b> , e32537	3.4	0
5	Personalized Care in Late-Stage Parkinson's Disease: Challenges and Opportunities. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12, 813	3.6	0
4	Reply to: Late-stage Parkinson's disease: the Barcelona and Lisbon cohorts. Past phenomenology and today's clinical needs. <i>Journal of Neurology</i> , <b>2011</b> , 258, 920-920	5.5	
3	Bou Rire Prodromique—Reply to a Note. <i>Cerebrovascular Diseases</i> , <b>2004</b> , 17, 350-350	3.2	
2	RimabotulinumtoxinB <b>2012</b> , 452-462		
1	Letter to the Editor.. <i>Journal of Paediatrics and Child Health</i> , <b>2022</b> ,	1.3	

